St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold

In the world of essential oils, sandalwood oil is like gold.

Australian sandalwood producer TFS Corporation, through its US joint venture entity Santalis Pharmaceuticals, is about to ship 100 kilograms of oil to an unidentified global pharmaceutical company - at $US4,500 per kilogram.

One kilogram of sandalwood oil is equivalent to about one litre.

The oil will be used in a range of dermatology products to be launched in the United States later in 2014.

The oil is the first to be produced from TFS Corp's sandalwood plantations at Kununarra in the Ord River region of Western Australia.

The first plantation was established in 1999.

Chief executive Frank Wilson said the first shipment of oil to a major pharmaceutical customer proved the company could grow a tree, mill it, distill it and sell it at very profitable prices.

"It's a big breakthrough for us, and we think it's the first of many to come in the pharmaceutical and medicinal market," he told AAP.

For reasons of confidentiality, Mr Wilson said he could not reveal customer's identity, or the skin conditions for which the sandalwood oil would be used to treat.

But the number of global dermatological companies is very small, and includes Swiss-based Galderma, which was recently taken over by Nestle.

Sandalwood trees take about 15 years to mature, growing about eight metres tall and to over 100kg in mass, Mr Wilson said.

About 20kg of that mass is heartwood - the aromatic wood in the inner circle of the tree from which the oil is extracted.

The heartwood from a good sandalwood tree can produce 600 to 700ml of oil, or used to make fine furniture and wood carvings.

The outer wood of the tree can be turned into very fine chips and sold to the incense market.

Mr Wilson said TFS Corp's plantations were still relatively small and were expected to produce a few tons of sandalwood oil per annum over the next few years.

"We're starting to hit our straps big time, and I think it will only get better as we start to get into our bigger harvests and our bigger plantations," he said.

The prices paid for sandalwood were high due to strong global demand from the cosmetics, fragrance, pharmaceutical, furniture and art sectors, and its limited supply.

TFS Corp's sandalwood was attracting increasing attention from the pharmaceutical sector, and Chinese and other Asian wood markets, Mr Wilson said.

The Chinese wood market was willing to pay even more for sandalwood than the pharmaceutical sector, and the market in China was promising, he said. back

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more